Following successful phase 3 trial results, Viridian Therapeutics’ veligrotug, an intravenously delivered treatment for thyroid eye disease (TED), has been granted US Food and Drug Administration (FDA) Breakthrough Therapy Designation.
Higher levels of 'good’ cholesterol' were associated with a 5% greater risk of developing glaucoma
This year, the Auckland University Medical Students' Association (AUMSA) ‘pacemaker’ team laced up their sneakers and hit the pavement for Auckland's Round the Bays for a day to remember! Under sunny skies, and with spirits high, it was a celebration of camaraderie, connection and the friendships th
A new antibody-based treatment regenerates retinal nerves in mouse models, with the effects lasting more than six months, said its South Korean developers. Writing in Nature Communications, resea
EssilorLuxottica has unveiled new six-year clinical data reinforcing the long-term efficacy of Essilor Stellest lenses in managing myopia progression and axial elongation in children and young adults.
A patient’s debilitating and baffling case of uveitis was finally resolved, after four years, by using metagenomics
Eye Health Aotearoa (EHA) co-chair Chrissie Cowan has been recognised as one of 100 Māori leaders in health by Te Rau Ora (formerly Te Rau Matatini) for her contribution, service, vision, dedication a
In a small study, US researchers found dual-focus (DF) contact lenses (CLs) were effective in teenagers and young adults with high myopia.
A new level of insight for anti-VEGF therapy planning for neovascular age-related macular degeneration (nAMD) patients is expected with Heidelberg and deepeye Medical’s collaboration, Deepeye Therapy Planning Support (TPS).
Moorfields Eye Hospital consultant ophthalmologists saved the sight of 24 Bangladeshi students over two days of complex surgeries. Drs Mahi Muqit and Niaz Islam were invited to Dhaka by Bangla
Improving access to eye examinations and spectacles is a global priority; however, in some inner-city Auckland communities up to 50% of people with vision impairment have never received an eye examination.
Attracting attention on Paragon Care’s Designs for Vision (DFV) stand was a new, small pachymeter, Occuity’s PM1 Pachymeter, being unveiled for the first time in New Zealand and Australia.